Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules
02 mai 2024 08h30 HE
|
Palisade Bio, Inc.
Carlsbad, CA, May 02, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with...
Ocean Biomedical (NASDAQ: OCEA) Announces New Patent for Anti-Fibrosis Discovery with Allowance in Alcoholic Liver Disease and Multiple Fibrotic Conditions, Leading Causes of Death in the U.S.
29 août 2023 08h01 HE
|
Ocean Biomedical, Inc.
Ocean’s small molecule candidate significantly controls fibrosis progression in idiopathic pulmonary fibrosis (IPF) and Hermansky-Pudlak Syndrome (HPS) in multiple testing models. Patent granted for...
CORBUS PHARMACEUTICALS ANNOUNCES ADJOURNMENT OF ANNUAL MEETING
19 mai 2021 09h20 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, May 19, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative...
Corbus Pharmaceuticals Announces Topline Results from RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis
08 sept. 2020 07h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Topline data showed no significant differences in the primary and secondary endpoints when comparing lenabasum to placebo, both added to background drug therapyUnprecedented improvement was observed...
Corbus Pharmaceuticals Appoints George Golumbeski, Ph.D., to Board of Directors
08 juil. 2020 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Dr. Golumbeski formerly led corporate and business development at Celgene and NovartisAppointment adds unique skill set to Corbus Board ahead of several key data readouts this summer Norwood, MA,...
Corbus Pharmaceuticals Reports Last Subject Visit in RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis
27 mai 2020 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Topline data on schedule for summer 2020Systemic sclerosis (SSc) is a rare, serious and life-threatening autoimmune disease affecting ~200,000 people in the U.S., EU and JapanThere are no FDA-approved...
Corbus Pharmaceuticals Reports 2019 Second Quarter Financial Results and Provides Clinical and Corporate Updates
08 août 2019 07h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Clinical development of lenabasum on target for 2020 data readouts in lead indications systemic sclerosis and cystic fibrosis; diseases affect ~270,000 people total in U.S., EU and Japan CRB-4001 on...
Corbus Pharmaceuticals to Present at the Oppenheimer 29th Annual Healthcare Conference
11 mars 2019 08h35 HE
|
Corbus Pharmaceuticals Holdings, Inc.
- Presentation with live audio webcast on Tuesday, March 19, 2019 at 2:10 p.m. ET- Norwood, MA, March 11, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or...
Corbus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
25 janv. 2019 09h01 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, Jan. 25, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company), a clinical stage drug development company with the industry’s leading...
Corbus Pharmaceuticals Initiates “DETERMINE” Phase 3 Study in Dermatomyositis
17 déc. 2018 07h00 HE
|
Corbus Pharmaceuticals Holdings, Inc.
DM is a rare systemic autoimmune disease that affects ~80,000 individuals in the U.S., EU and Japan and has a 5-year mortality rate as high as 30% This marks Company’s second Phase 3 program in rare...